PET显像在自身免疫性脑炎诊断与预后预测中的应用

doi:10.3969/j.issn.1672-6731.2025.12.002

中国现代神经疾病杂志 ›› 2025, Vol. 25 ›› Issue (12): 1095-1106. doi: 10.3969/j.issn.1672-6731.2025.12.002

2 PET显像在自身免疫性脑炎诊断与预后预测中的应用

王宁¹, 孙越乾¹, 王群^1,2,3,4

1 100070 首都医科大学附属北京天坛医院神经病学中心;
2 450046 郑州大学第一附属医院神经内科;
3 100070 北京, 国家神经系统疾病临床医学研究中心;
100069 北京脑重大疾病研究院

收稿日期:2025-11-02 发布日期:2026-01-08
通讯作者: 王群，Email：wangq@ccmu.edu.cn
基金资助:
首都卫生发展科研专项（项目编号：首发2024-1-2041）；国家自然科学基金资助项目（项目编号：82371449）；国家自然科学基金资助项目（项目编号：82501734）；国家自然科学基金资助项目（项目编号：U24A20695）；国家重点研发计划“常见多发病防治研究”重点专项（项目编号：2022YFC2503800）；中国博士后科学基金资助项目（项目编号：2024M762180）

Application of PET imaging in the diagnosis and prognosis prediction of autoimmune encephalitis

WANG Ning¹, SUN Yue-qian¹, WANG Qun^1,2,3,4

1 Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;
2 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450046, He'nan, China;
3 China National Clinical Research Center for Neurological Diseases, Beijing 100070, China;
4 Beijing Institute of Brain Disorders, Beijing 100069, China

Received:2025-11-02 Published:2026-01-08
Supported by:
This study was supported by Capital Health Research and Development of Special Project (No. 2024- 1-2041), the National Natural Science Foundation of China (No. 82371449, 82501734, U24A20695), National Key Research and Development Program of China "Common Disease Prevention and Control Research" Key Project (No. 2022YFC2503800), and China Postdoctoral Science Foundation (No. 2024M762180).

摘要/Abstract

摘要： PET显像在自身免疫性脑炎的诊断与治疗过程中具有重要价值，可以借助检测放射性示踪剂在脑内分布，直观反映大脑代谢活动，呈现不同抗体类型自身免疫性脑炎代谢变化模式；还可以对疾病进展和治疗效果进行有效监测，为临床决策提供有力依据。本文拟阐述不同抗体自身免疫性脑炎¹⁸F-FDG PET代谢模式，以及其他新型PET技术在自身免疫性脑炎中的应用，以期有助于自身免疫性脑炎的精准诊断与治疗。

关键词: 脑炎, 神经系统自身免疫疾病, 抗N-甲基-D-门冬氨酸受体脑炎, 正电子发射断层显像术, tau蛋白质类, 综述

Abstract: PET imaging plays a crucial role in the diagnosis and management of autoimmune encephalitis (AE). By detecting the distribution of radiotracers, PET provides a direct visualization of cerebral metabolic activity, revealing distinct metabolic patterns associated with different types of AE. Furthermore, it allows for effective monitoring of disease progression and therapeutic response, offering robust support for clinical decision-making. This review aims to elucidate the cerebral ¹⁸F-FDG PET metabolic patterns in AE associated with various antibodies, and to discuss the applications of other emerging PET tracers, with the goal of advancing the precise diagnosis and treatment of this condition.

Key words: Encephalitis, Autoimmune diseases of the nervous system, Anti-N-methyl-D-aspartate receptor encephalitis, Positron-emission tomography, Tau proteins, Review

王宁, 孙越乾, 王群. PET显像在自身免疫性脑炎诊断与预后预测中的应用[J]. 中国现代神经疾病杂志, 2025, 25(12): 1095-1106.

WANG Ning, SUN Yue-qian, WANG Qun. Application of PET imaging in the diagnosis and prognosis prediction of autoimmune encephalitis[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2025, 25(12): 1095-1106.

https://journal11.magtechjournal.com/cjcnn/CN/Y2025/V25/I12/1095

参考文献

[1] Guasp M, Dalmau J. Autoimmune encephalitis[J]. Med Clin North Am, 2025, 109:443-461.
[2] Seery N, Wesselingh R, Beech P, Broadley J, Griffith S, Rushen T, Beharry J, Tan C, Chiniforoush N, McLaughlin L, Ter Horst L, Forcadela M, Tan T, Kazzi C, Nesbitt C, Buzzard K, Duncan A, Halliday A, D'Souza W, Tran Y, Van Der Walt A, Skinner G, Swayne A, Malpas CB, Brodtmann A, Gillis D, Taylor B, Butler EG, Kalincik T, Seneviratne U, Macdonell R, Blum S, Ramanathan S, Reddel SW, Hardy TA, O'Brien TJ, Sanfilippo P, Butzkueven H, Monif M; Australian Autoimmune Encephalitis Consortium. Multimodal prognostication of autoimmune encephalitis:an Australian autoimmune encephalitis consortium study[J]. J Neurol, 2025, 272:361.
[3] Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis:relevance for clinical practice and hippocampal function[J]. Neuroscience, 2015, 309:68-83.
[4] Ball C, Fisicaro R, Morris L 3rd, White A, Pacicco T, Raj K, Agarwal A, Lee WC, Yu FF. Brain on fire:an imaging-based review of autoimmune encephalitis[J]. Clin Imaging, 2022, 84:1-30.
[5] Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 4:e352.
[6] Kalra S, Tripathi M, Tripathi M, Sonar RS, Pandey AK, Jaleel J, Singh RK, Kumar P, Damle NA, Bal C. Role of FDG PET/CT in definitive and presumed autoimmune encephalitis[J]. Nucl Med Commun, 2024, 45:121-127.
[7] Wei YC, Tseng JR, Wu CL, Su FC, Weng WC, Hsu CC, Chang KH, Wu CF, Hsiao IT, Lin CP. Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis:case report and literature review[J]. Brain Behav, 2020, 10:e01540.
[8] Bordonne M, Chawki MB, Doyen M, Kas A, Guedj E, Tyvaert L, Verger A. Brain ¹⁸F-FDG PET for the diagnosis of autoimmune encephalitis:a systematic review and a meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2021, 48:3847-3858.
[9] Maudes E, Planagumà J, Marmolejo L, Radosevic M, Serafim AB, Aguilar E, Sindreu C, Landa J, García-Serra A, Mannara F, Cunquero M, Smit A, Milano C, Peixoto-Moledo P, Guasp M, Ruiz-García R, Gray SM, Spatola M, Loza-Alvarez P, Sabater L, Matute C, Dalmau J. Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis[J]. Brain, 2025, 148:2023-2037.
[10] de Bruijn MAAM, Leypoldt F, Dalmau J, Lee ST, Honnorat J, Clardy SL, Irani SR, Easton A, Kunchok A, Titulaer MJ. Autoimmune encephalitis[J]. Nat Rev Dis Primers, 2025, 11:65. P, Chen X, Zuo C.
[11] Ge J, Deng B, Guan Y, Bao W, Wu Distinct cerebral ¹⁸F-FDG PET metabolic patterns in anti-N-methyl-D-aspartate receptor encephalitis patients with different trigger factors[J]. Ther Adv Neurol Disord, 2021, 14:1756286421995635.
[12] Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis:case series and analysis of the effects of antibodies[J]. Lancet Neurol, 2008, 7:1091-1098.
[13] Cleaver J, Chungath R, Gimson A, Strippel C, Ceronie B, Soleimani B, Johnson T, Muscal E, Fisher K, Jiang Y, Erickson TA, Murray KO, Hovet STF, Poulsen CA, Magnussen AS, Dumez P, Ronca S, Häusler M, Quade A, Swayne A, Blaabjerg M, Nissen M, Sandweiss AJ, Honnorat J, Dale R, Lim M, Eyre M, Nosadini M, Handunnetthi L, Irani SR, Handel AE. Clinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis:a systematic review and meta-analysis[J]. J Infect, 2025, 91:106566. L, Zhao J.
[14] Wang Y, Zhou Q, Dai Z, Qiu Y, Zhou H, Feng Clinical and brain MRI characteristics of patients with anti-N-methyl-D-aspartate receptor encephalitis:a 10-year retrospective study[J]. Eur Neurol, 2025, 88:71-81.
[15] Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents[J]. Ann Neurol, 2009, 66:11-18. R,
[16] Kerik-Rotenberg N, Diaz-Meneses I, Hernandez-Ramirez Muñoz-Casillas R, Reynoso-Mejia CA, Flores-Rivera J, Espinola-Nadurille M, Ramirez-Bermudez J, Aguilar-Palomeque C. A metabolic brain pattern associated with anti-N-methyl-D-aspartate receptor encephalitis[J]. Psychosomatics, 2020, 61:39-48.
[17] Yuan L, Mao G, Zhang Y, Xu Y, Chen Q, Shan B, Cui T, Ai L. Typical metabolic pattern of ¹⁸F-FDG PET in anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features[J]. BMC Neurosci, 2023, 24:51. E, Sardaripour A, Seyedi SA,
[18] Nabizadeh F, Ramezannezhad Salehi N, Rezaeimanesh N, Naser Moghadasi A.[¹⁸F]FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis:a systematic review[J]. Neurol Sci, 2022, 43:4701-4718. Mundlamuri RC, Alladi S, Nashi S,
[19] Jha S, Nagaraj C, Kenchaiah R, Mahadevan A, Bhat M, Saini J, Netravathi M. FDG-PET in autoimmune encephalitis:utility, pattern of abnormalities, and correlation with autoantibodies[J]. Ann Indian Acad Neurol, 2022, 25:1122-1129. L, Cui R.
[20] Yuan J, Guan H, Zhou X, Niu N, Li F, Cui Changing brain metabolism patterns in patients with ANMDARE:serial 18 F-FDG PET/CT findings J. Clin Nucl[] Med, 2016, 41:366-370.
[21] Bergeret S, Birzu C, Meneret P, Giron A, Demeret S, Marois C, Cousyn L, Rozenblum L, Laurenge A, Alentorn A, Navarro V, Psimaras D, Kas A. Brain metabolic alterations in seropositive autoimmune encephalitis:an ¹⁸F-FDG PET study[J]. Biomedicines, 2023, 11:506.
[22] Zhang C, Hao Y, Huang G, Xin M, Bai S, Guan Y, Liu J. Hypometabolism of the left middle/medial frontal lobe on FDG-PET in anti-NMDA receptor encephalitis:comparison with MRI and EEG findings[J]. CNS Neurosci Ther, 2023, 29:1624-1635.
[23] Li G, Liu X, Yu T, Ren J, Wang Q. Positron emission tomography in autoimmune encephalitis:clinical implications and future directions[J]. Acta Neurol Scand, 2022, 146:708-715.
[24] Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A. Decreased occipital lobe metabolism by FDG-PET/CT:an anti-NMDA receptor encephalitis biomarker[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 5:e413.
[25] Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D. Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis:a systematic review[J]. J Clin Neurosci, 2018, 52:54-59.
[26] Dai Y, Zhu Z, Tang Y, Xiao L, Liu X, Zhang M, Xiao B, Hu K, Long L, Xie Y, Hu S. The clinical and predictive value of ¹⁸F-FDG PET/CT metabolic patterns in a clinical Chinese cohort with autoimmune encephalitis[J]. CNS Neurosci Ther, 2024, 30:e14821.
[27] Novy J, Allenbach G, Bien CG, Guedj E, Prior JO, Rossetti AO. FDG-PET hyperactivity pattern in anti-NMDAR encephalitis[J]. J Neuroimmunol, 2016, 297:156-158.
[28] Kosek S, Kilsved E, Danfors T, Cunningham JL, Pavel R, Rostedt Punga A, Burman J, Fällmar D. Regional metabolic abnormalities in autoimmune encephalitis:a Meta-analysis of 498 cases with brain FDG PET[J]. Clin Nucl Med, 2025, 50:208-213.
[29] Lagarde S, Lepine A, Caietta E, Pelletier F, Boucraut J, Chabrol B, Milh M, Guedj E. Cerebral (18) fluorodeoxy-glucose positron emission tomography in paediatric anti N-methyl-D-aspartate receptor encephalitis:a case series[J]. Brain Dev, 2016, 38:461-470.
[30] London K, Howman-Giles R. Normal cerebral FDG uptake during childhood[J]. Eur J Nucl Med Mol Imaging, 2014, 41:723-735.
[31] Antonio M, Cerne D, Sara B, Sara B, Enrico M, Pietro B, Stefano M, Chiara M, Silvia S, Mobilia EM, Cappa SF, Luana B, Diego F, Gastaldi M. Retrograde amnesia in LGI1 and CASPR2 limbic encephalitis:two case reports and a systematic literature review[J]. Eur J Neurol, 2025, 32:e70113.
[32] Baudin P, Cousyn L, Navarro V. The LGI1 protein:molecular structure, physiological functions and disruption-related seizures[J]. Cell Mol Life Sci, 2021, 79:16.
[33] Hébert J, Riche B, Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Psimaras D, Alentorn A, Berzero G, Desestret V, Rabilloud M, Honnorat J. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7:e883.
[34] Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis[J]. Ann Neurol, 2011, 69:892-900.
[35] Li TR, Zhang YD, Wang Q, Shao XQ, Lv RJ. Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis[J]. CNS Neurosci Ther, 2021, 27:1173-1181.
[36] Joubert B. The neurobiology and immunology of CASPR2-associated neurological disorders[J]. Rev Neurol (Paris), 2024, 180:950-956.
[37] Cornacchini S, Farina A, Contento M, Berti V, Biggi M, Barilaro A, Massacesi L, Damato V, Rosati E. Long-term-video monitoring EEG and ¹⁸F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis:a case report[J]. Front Neurol, 2022, 13:949240.
[38] Liang M, Niu N, Jia C, Fan S, Liu L, Cui R, Guan H. Diagnostic superiority of 18 F-FDG PET over MRI in detecting anti-LGI1 autoimmune encephalitis:a comparative study with insights into faciobrachial dystonic seizures mechanisms and recurrence identification[J]. Clin Nucl Med, 2023, 48:e516-e522.
[39] Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, Psimaras D, Habert MO, Baulac M, Delattre JY, Honnorat J; Collaborators. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis[J]. Brain, 2016, 139(Pt 4):1079-1093.
[40] Zhao Y, Yuan Y, Wang RZ, Cui M, Chen SF, Chen KL, Li MM, Huang YY, Zhang HN, Zhang Y, Zhao M, Tian H, Sun L, Yu JT. Clinical, electroencephalogram and imaging characteristics of patients with anti-LGI1 antibody encephalitis:a multicenter cohort study[J]. CNS Neurosci Ther, 2025, 31:e70414.
[41] Sánchez-Ordúz L, Gállego Pérez-Larraya J, Grisanti F, Centeno M, Arbizu J. CASPR2 antibody-associated limbic encephalitis:contribution of visual aided analysis of ¹⁸F-FDG PET images using normal database comparison[J]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2020, 39:92-95.
[42] Marongiu A, Galleri P, Mura A, Solla P, Madeddu G, Spanu A, Nuvoli S. ¹⁸F-FDG brain PET/CT metabolic imaging in patients with suspected autoimmune encephalitis (AE) in the early stage:can the procedure play a complementary diagnostic role[J]?Brain Sci, 2025, 15:113.
[43] Seniaray N, Verma R, Ranjan R, Belho E, Mahajan H. Metabolic imaging patterns on ¹⁸F-FDG PET in acute and subacute LGI1 autoimmune limbic encephalitis[J]. Clin Nucl Med, 2021, 46:e27-e28.
[44] Sadaghiani MS, Roman S, Diaz-Arias LA, Habis R, Venkatesan A, Probasco JC, Solnes LB. Comparison of quantitative FDG-PET and MRI in anti-LGI1 autoimmune encephalitis[J]. Neuroradiology, 2023, 65:1225-1238.
[45] Liu X, Shan W, Zhao X, Ren J, Ren G, Chen C, Shi W, Lv R, Li Z, Liu Y, Ai L, Wang Q. The clinical value of ¹⁸F-FDG-PET in autoimmune encephalitis associated with LGI1 antibody[J]. Front Neurol, 2020, 11:418.
[46] Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL. Clinical spectrum of high-titre GAD65 antibodies[J]. J Neurol Neurosurg Psychiatry, 2021, 92:645-654.
[47] Zhang Z, Fan S, Ren H, Zhou L, Guan H. Clinical characteristics and prognosis of anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis[J]. BMC Neurol, 2021, 21:490.
[48] Gagnon MM, Savard M. Limbic encephalitis associated with GAD65 antibodies:brief review of the relevant literature[J]. Can J Neurol Sci, 2016, 43:486-493.
[49] Vacchiano V, Giannoccaro MP, Napolitano RP, Liguori R, Allegri V, Rinaldi R, Spinardi L. Combined brain positron emission tomography/magnetic resonance imaging in GABAA receptor encephalitis[J]. Eur J Neurol, 2019, 26:e88-e89.
[50] Kojima G, Inaba M, Bruno MK. PET-positive extralimbic presentation of anti-glutamic acid decarboxylase antibody-associated encephalitis[J]. Epileptic Disord, 2014, 16:358-361.
[51] Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome:insights into a complex autoimmune disorder[J]. J Neurol Neurosurg Psychiatry, 2015, 86:840-848.
[52] Wang K, Zhao X, Yuan L, Chen Q, Wang Q, Ai L. Cortical metabolic characteristics of anti-leucine-rich glioma-inactivated 1 antibody encephalitis based on ¹⁸F-FDG PET[J]. Front Neurol, 2023, 14:1100760.
[53] Andersen JV. The glutamate/GABA-glutamine cycle:insights, updates, and advances[J]. J Neurochem, 2025, 169:e70029.
[54] Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance[J]. Exp Biol Med (Maywood), 2021, 246:1069-1083.
[55] Hashimoto K, Nakamura T, Fujita Y, Furuta M, Makioka K, Shimoda Y, Iizuka T, Ikeda Y. Coupling of cortical hyperintense signals and increased glucose metabolism in a case of anti-GABAA receptor antibody-associated encephalitis[J]. Intern Med, 2023, 62:3545-3548.
[56] Cezar M, Belletto R, Polidori S, Soive L, Campitiello M, Legros PO, Egea J, Plastino F, Benaiteau M, Tyvaert L, Tortora G, Longo R. Managing paraneoplastic GABA BR-related limbic encephalitis in a patient with a small cell lung cancer receiving an Immune-Checkpoint Inhibitor (ICI) therapy:description of a case report[J]. BMC Neurol, 2025, 25:467.
[57] Liu X, Yu T, Zhao X, Li G, Lv R, Ai L, Wang Q. ¹⁸F-fluorodeoxy-glucose positron emission tomography pattern and prognostic predictors in patients with anti-GABAB receptor encephalitis[J]. CNS Neurosci Ther, 2022, 28:269-278.
[58] Kim TJ, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Shin YW, Lee KJ, Jung KH, Kim YS, Park KI, Chu K, Lee SK. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis[J]. J Neuroimmunol, 2014, 270(1/2):45-50.
[59] Fan S, Jia C, Liang M, Ren H, Zhang T, Li Q, Huang Z, Yen TC, OuYang C, Cui R, Guan H. Patterns of Tau pathology in patients with anti-IgLON5 disease visualized by Florzolotau (¹⁸F) PET[J]. J Neurol, 2025, 272:115.
[60] Wang C, Kong F, Yu X, Li Y, Yang M, Si Z, Liu R, Hu K, Yang B. Clinical characteristics and outcome in patients with anti-AMPAR2 encephalitis:a case series and literature review[J]. Front Hum Neurosci, 2025, 19:1586005.
[61] Milano C, Saylam E, Papi C, Marmolejo L, Sankovic A, Reinecke R, Kerstens J, Pizzanelli C, Simabukuro MM, Benaiteau M, Joubert B, Gastaldi M, Dutra LA, Leypoldt F, Jansen M, Kawachi I, Akiyama H, Boy N, Bozzetti S, Christensen PB, Businaro P, Dinoto A, Friedman-Korn T, Fujiwara U, Fukumoto T, Fuse K, Hooshmand SI, Hurst L, Iorio R, Korn-Lubetzki I, Rodrigues AFL, Mariotto S, Michael J, Morimoto Y, Neuteboom RF, Piquet AL, Rossetti AO, Rumpler-Kreiner S, Santoro JD, Schwendinger F, Shen B, Syrbe S, Troger J, Wagner I, Bien CG, Martinez-Hernandez E, Armangue T, Höftberger R, Iizuka T, Titulaer MJ, Honnorat J, Graus F, Dalmau JO, Magaña S, Spatola M. Clinical characterization and long-term outcome in children and adults with anti-AMPA receptor encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200453.
[62] Cong H, Yuan L, Zheng P, Xu X, Dong W, Tian D, Yin L, Ma Y, Song T, Zhao Y, Xu Y, Zhang M, Liu B, Chang G, Sun K, Ma W, Ai L, Xu W. ¹⁸F-FDG PET/CT reveals characteristic prefrontal-posterior cingulate hypometabolism in anti-AMPAR encephalitis to understand cerebral function:insights from an eight-patient cohort[J]. CNS Neurosci Ther, 2025, 31:e70633.
[63] Grativvol RS, Cavalcante WCP, Castro LHM, Nitrini R, Simabukuro MM. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes[J]. Curr Oncol Rep, 2018, 20:92. Stojanova V, Prior JO, Dalmau J, Rossetti AO.
[64] Spatola M, Serial brain ¹⁸FDG-PET in anti-AMPA receptor limbic encephalitis[J]. J Neuroimmunol, 2014, 271(1/2):53-55.
[65] Wang X, Zhao C, Chen Q, Yu W, Zhao S, Wang P, Sun L, Xu L, Xu Y. Anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2 encephalitis with olfactory hallucination:a case report and literature review[J]. Front Immunol, 2025, 16:1444053.
[66] Jia Y, Li M, Wang H, Zhang M, Wang Y. The peculiar clinical symptoms and treatment of limbic encephalitis associated with AMPA receptor antibody[J]. Eur Neurol, 2021, 84:206-211.
[67] Gaig C, Sabater L. New knowledge on anti-IgLON5 disease[J]. Curr Opin Neurol, 2024, 37:316-321.
[68] Graus F, Sabater L, Gaig C, Gelpi E, Iranzo A, Dalmau JO, Santamaria J. Anti-IgLON5 disease 10 years later:what we know and what we do not know[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200353.
[69] Hartung TJ, Bartels F, Kuchling J, Krohn S, Leidel J, Mantwill M, Wurdack K, Yogeshwar S, Scheel M, Finke C. MRI findings in autoimmune encephalitis[J]. Rev Neurol (Paris), 2024, 180:895-907.
[70] Seniaray N, Verma R, Ranjan R, Belho E, Mahajan H. Lewy body dementia associated with anti-IgLON 5 encephalitis detected on ¹⁸F fluorodeoxyglucose positron emission tomography/computed tomography and 99mTc-TRODAT single-photon emission computed tomography/computed tomography[J]. Indian J Nucl Med, 2022, 37:94-96.
[71] Zhang W, Niu N, Cui R. Serial ¹⁸F-FDG PET/CT findings in a patient with IgLON5 encephalopathy[J]. Clin Nucl Med, 2016, 41:787-788.
[72] Li EC, Zhang TY, Cai MT, Su SY, Shen CH, Lai QL, Zhang YX. Clinical and paraclinical characterizations, management, and prognosis in DPPX antibody-associated encephalitis:a systematic review[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200350.
[73] Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody:frequency, clinical accompaniments, and outcomes in 20 patients[J]. Neurology, 2014, 83:1797-1803.
[74] Dominguez L, McKeon A, Tobin WO, Lopez-Chiriboga S. Long term outcomes in patients with anti-DPPX autoimmunity[J]. J Neuroimmunol, 2023, 384:578214.
[75] Zhou Q, Zhu X, Meng H, Zhang M, Chen S. Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia[J]. J Neuroimmunol, 2020, 339:577114.
[76] Piepgras J, Höltje M, Michel K, Li Q, Otto C, Drenckhahn C, Probst C, Schemann M, Jarius S, Stöcker W, Balint B, Meinck HM, Buchert R, Dalmau J, Ahnert-Hilger G, Ruprecht K. Anti-DPPX encephalitis:pathogenic effects of antibodies on gut and brain neurons[J]. Neurology, 2015, 85:890-897.
[77] Wan W, Pan Y, Chen Y, Bai S, Yao X, Lin Y, Wu J, Ni L, Mei Y, Qiu H, Zhou Y, Hao Y, Guan Y. The effect of double filtration plasmapheresis and corticosteroids on patients with anti-dipeptidyl-peptidase-like protein 6 encephalitis J. Ther Apher Dial, 2024, 28:141-151.[]
[78] Guo K, Liu X, Gong X, Li A, Liu Y, Li X, Zhou D, Hong Z. Autoimmune encephalitis with mGluR5 antibodies:a case series from China and review of the literature[J]. Front Immunol, 2023, 14:1146536.
[79] Deng M, Xiong J, Kong Z, Wang X, Li T. Case report. Clinical features and management of anti-mGluR1 encephalitis:case illustration and review of the literature[J]. Front Integr Neurosci, 2025, 19:1580767.
[80] Li YX, Wang RY, Hao YL. Clinical characteristics, treatment, and outcomes in anti-metabotropic glutamate receptor-1 encephalitis:a systematic review[J]. Clin Neurol Neurosurg, 2025, 259:109229.
[81] Khojah O, Makkawi S, Alghamdi S. Anti-mGluR1 encephalitis:case illustration and systematic review[J]. Front Neurol, 2023, 14:1142160.
[82] Sun Y, Tao JX, Han X, Wang X, Zhu Y, Lian Y, Ren G, Wang Q. Clinical features and brain MRI volumetric changes in anti-mGluR5 encephalitis[J]. Ann Clin Transl Neurol, 2023, 10:1407-1416. KS, Ferguson SSG. Noncanonical metabotropic
[83] Abd-Elrahman glutamate receptor 5 signaling in Alzheimer's disease[J]. Annu Rev Pharmacol Toxicol, 2022, 62:235-254. Machado L,
[84] Machado LS, Vidor P, Perquim L, Limberger C, Rocha A, Soares C, Rahmouni N, S Brum W, Bellaver B, Ferreira PCL, Borelli WV, da Costa JC, Malpetti M, Pascoal TA, Souza DO, Edison P, Blennow K, Zetterberg H, Ashton NJ, Benedet AL, Serrano-Pozo A, Rosa-Neto P, Zimmer ER. Association between FDG-and TSPO-PET signals across human and animal studies investigating neurodegenerative conditions:a systematic review[J]. Mol Psychiatry, 2026, 31:559-575.
[85] Wijesinghe SS, Rowe JB, Mason HD, Allinson KSJ, Thomas R, Vontobel DS, Fryer TD, Hong YT, Bacioglu M, Spillantini MG, van den Ameele J, O'Brien JT, Kaalund S, Malpetti M, Quaegebeur A. Post-mortem validation of in vivo TSPO PET as a microglial biomarker[J]. Brain, 2025, 148:1904-1910. R,
[86] Bodini B, Poirion E, Tonietto M, Benoit C, Palladino Maillart E, Portera E, Battaglini M, Bera G, Kuhnast B, Louapre C, Bottlaender M, Stankoff B. Individual mapping of innate immune cell activation is a candidate marker of patient-specific trajectories of worsening disability in multiple sclerosis[J]. J Nucl Med, 2020, 61:1043-1049. A, Ouellette
[87] Herranz E, Treaba CA, Barletta VT, Mehndiratta R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis[J]. Brain, 2024, 147:2566-2578. VT, Herranz E, Treaba CA, Mehndiratta A, Ouellette
[88] Barletta R, Granberg T, Klawiter EC, Ionete C, Sloane JA, Mainero C. In vivo characterization of microglia and myelin relation in multiple sclerosis by combined 11C-PBR28 PET and synthetic MRI[J]. J Neurol, 2023, 270:3091-3102. H, Blennow
[89] Al-Abdulrasul H, Ajalin R, Tuisku J, Zetterberg K, Vahlberg T, Ekblad L, Helin S, Forsback S, Rinne JO, Brück A. Neuroinflammation in Parkinson's disease:a study with[11 C]PBR28 PET and cerebrospinal fluid markers J.[] Parkinsonism Relat Disord, 2025, 130:107177.
[90] Rodríguez-Chinchilla T, Quiroga-Varela A, Molinet-Dronda F, Belloso-Iguerategui A, Merino-Galan L, Jimenez-Urbieta H, Gago B, Rodriguez-Oroz MC.[18 F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration[J]. Eur J Nucl Med Mol Imaging, 2020, 47:2602-2612.
[91] Carter K, Cicero S, Rissanen E, Dubey S, Weiner HL, Singhal T. Assessment of microglial activation in Alzheimer disease using 18 F-PBR06 PET[J]. Clin Nucl Med, 2023, 48:643-644.
[92] López-Picón FR, Keller T, Bocancea D, Helin JS, Krzyczmonik A, Helin S, Damont A, Dollé F, Rinne JO, Haaparanta-Solin M, Solin O. Direct comparison of[¹⁸F]F-DPA with[¹⁸F]DPA-714 and[11C]PBR28 for neuroinflammation imaging in the same Alzheimer's disease model mice and healthy controls[J]. Mol Imaging Biol, 2022, 24:157-166.
[93] Wang J, Jin L, Zhang X, Yu H, Ge J, Deng B, Li M, Zuo C, Chen X. Activated microglia by ¹⁸F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis[J]. J Neuroimmunol, 2022, 368:577879.
[94] Shen R, Shen D, Zhou Q, Zhang M, Chen S. Antibody-mediated autoimmune encephalitis evaluated by ¹⁸F-DPA714 PET/MRI[J]. Brain Behav Immun Health, 2022, 26:100535.
[95] Wang J, Ge J, Jin L, Deng B, Tang W, Yu H, Zhang X, Liu X, Xue L, Zuo C, Chen X. Characterization of neuroinflammation pattern in anti-LGI1 encephalitis based on TSPO PET and symptom clustering analysis[J]. Eur J Nucl Med Mol Imaging, 2023, 50:2394-2408.
[96] Wang J, Ge J, Deng B, Lin H, Yang W, Sheng T, Tang W, Yu H, Zhang X, Li Y, Liu X, Zuo C, Chen X. Microglial activation visualized by[¹⁸F]-DPA714 PET is a potential marker of severity and prognosis for anti-LGI1 encephalitis[J]. Eur J Neurol, 2025, 32:e70107.
[97] Gelpi E, Reinecke R, Gaig C, Iranzo A, Sabater L, Molina-Porcel L, Aldecoa I, Endmayr V, Högl B, Schmutzhard E, Poewe W, Pfausler B, Popovic M, Pretnar-Oblak J, Leypoldt F, Matschke J, Glatzel M, Erro EM, Jerico I, Caballero MC, Zelaya MV, Mariotto S, Heidbreder A, Kalev O, Weis S, Macher S, Berger-Sieczkowski E, Ferrari J, Reisinger C, Klupp N, Tienari P, Rautila O, Niemelä M, Yilmazer-Hanke D, Guasp M, Bloem B, Van Gaalen J, Kusters B, Titulaer M, Fransen NL, Santamaria J, Dawson T, Holton JL, Ling H, Revesz T, Myllykangas L, Budka H, Kovacs GG, Lewerenz J, Dalmau J, Graus F, Koneczny I, Höftberger R. Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology:updated neuropathological research criteria of the disease-related tauopathy[J]. Acta Neuropathol, 2024, 148:53.
[98] Campetella L, Smolik K, Farina A, Joubert B, Muñiz-Castrillo S, Desestret V, Honnorat J. Neurodegeneration and the immune system:lessons from autoimmune encephalitis[J]. J Neurol, 2025, 272:359.
[99] Theis H, Bischof GN, Brüggemann N, Dargvainiene J, Drzezga A, Grüter T, Lewerenz J, Leypoldt F, Neumaier B, Wandinger KP, Ayzenberg I, van Eimeren T. In vivo measurement of tau depositions in anti-IgLON5 disease using[¹⁸F]PI-2620 PET[J]. Neurology, 2023, 101:e2325-e2330.
[100] Farina A, Villagrán-García M, Abichou-Klich A, Benaiteau M, Bernard E, Bouhour F, Desestret V, Joubert B, Picard G, Pinto AL, Pons L, Smolik K, Thobois S, Trouillet-Assant S, Honnorat J. Serum neurofilament light chain correlates with clinical severity and predicts mortality in anti-IgLON5 disease[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200498.
[101] Day GS, Gordon BA, McCullough A, Bucelli RC, Perrin RJ, Benzinger TLS, Ances BM. Flortaucipir (tau) PET in LGI1 antibody encephalitis[J]. Ann Clin Transl Neurol, 2021, 8:491-497.
[102] Lu J, Ge J, Yu H, Zhao G, Chen X. Colocalization of increased midbrain signals in neuroinflammation and tau PET imaging suggests the diagnosis of progressive supranuclear palsy[J]. Clin Nucl Med, 2024, 49:346-347.
[103] Wongso H, Harada R, Furumoto S. Current progress and future directions in non-Alzheimer's disease tau PET tracers[J]. ACS Chem Neurosci, 2025, 16:111-127.
[104] Strobel J, Müller HP, Ludolph AC, Beer AJ, Sollmann N, Kassubek J. New perspectives in radiological and radiopharmaceutical hybrid Imaging in progressive supranuclear palsy:a systematic review[J]. Cells, 2023, 12:2776.
[105] Sanchez JS, Becker JA, Jacobs HIL, Hanseeuw BJ, Jiang S, Schultz AP, Properzi MJ, Katz SR, Beiser A, Satizabal CL, O'Donnell A, DeCarli C, Killiany R, El Fakhri G, Normandin MD, Gómez-Isla T, Quiroz YT, Rentz DM, Sperling RA, Seshadri S, Augustinack J, Price JC, Johnson KA. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography[J]. Sci Transl Med, 2021, 13:eabc0655.
[106] Harada R, Furumoto S, Kudo Y, Yanai K, Villemagne VL, Okamura N. Imaging of reactive astrogliosis by positron emission tomography[J]. Front Neurosci, 2022, 16:807435.
[107] Bauer J, Bien CG. Neuropathology of autoimmune encephalitides[J]. Handb Clin Neurol, 2016, 133:107-120.
[108] Ballweg A, Klaus C, Vogler L, Katzdobler S, Wind K, Zatcepin A, Ziegler SI, Secgin B, Eckenweber F, Bohr B, Bernhardt A, Fietzek U, Rauchmann BS, Stoecklein S, Quach S, Beyer L, Scheifele M, Simmet M, Joseph E, Lindner S, Berg I, Koglin N, Mueller A, Stephens AW, Bartenstein P, Tonn JC, Albert NL, Kümpfel T, Kerschensteiner M, Perneczky R, Levin J, Paeger L, Herms J, Brendel M.[¹⁸F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases:preclinical proof of concept and first-in-human data[J]. J Neuroinflammation, 2023, 20:68.

选择文件类型/文献管理软件名称

选择包含的内容

2 PET显像在自身免疫性脑炎诊断与预后预测中的应用

Application of PET imaging in the diagnosis and prognosis prediction of autoimmune encephalitis

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邱炳辉, 杜佳澍, 钟晴蕾, 卓杰, 何山. 应重视下丘脑垂体功能障碍对重型颅脑创伤患者长期预后的影响[J]. 中国现代神经疾病杂志, 2025, 25(9): 779-783.
[2]	韩佳良, 张国斌. 小胶质细胞在颅脑创伤发病机制中的作用[J]. 中国现代神经疾病杂志, 2025, 25(9): 784-789.
[3]	潘景锡, 李文福, JalalKhan, 杜佳澍, 钟晴蕾, 包贇. 创伤性脑水肿病理学特征与治疗进展[J]. 中国现代神经疾病杂志, 2025, 25(9): 790-797.
[4]	廖希贤, 梅芬, 邱炳辉, 漆松涛, 钟晴蕾, 包贇. 生长激素在颅脑创伤的应用进展[J]. 中国现代神经疾病杂志, 2025, 25(9): 798-806.
[5]	郭一丁, 温佳奇, 刘勇, 薛蓉, 郭华, 郭毅. 轻型颅脑创伤影像学研究进展[J]. 中国现代神经疾病杂志, 2025, 25(9): 807-813.
[6]	王圆圆, 高阳, 赵翠, 朱明伟, 王振福. 边缘叶为主年龄相关性TDP-43脑病研究进展[J]. 中国现代神经疾病杂志, 2025, 25(9): 862-868.
[7]	巫嘉陵, 李惟华. 出血性卒中康复管理模式的优化与发展[J]. 中国现代神经疾病杂志, 2025, 25(8): 679-682.
[8]	杨璇, 张玥, 巫嘉陵. 后循环卒中前庭功能障碍特点及康复治疗[J]. 中国现代神经疾病杂志, 2025, 25(8): 683-688.
[9]	吴晓莉, 杜晓霞. 双位点经颅磁刺激技术在脑卒中后运动障碍中的康复治疗[J]. 中国现代神经疾病杂志, 2025, 25(8): 689-696.
[10]	徐光毓, 张梦茹, 孟金锭, 吕颖昕, 王文博, 王秋筠, 张峰. 脑卒中经皮穴位电刺激康复治疗[J]. 中国现代神经疾病杂志, 2025, 25(8): 697-704.
[11]	李梦琦, 杜勇, 田轶魁. 慢性心力衰竭与神经系统相互作用及其对脑心同治的启示[J]. 中国现代神经疾病杂志, 2025, 25(8): 732-738.
[12]	廖淑馨, 陈志颖. 脑出血急性期继发性脑缺血研究进展[J]. 中国现代神经疾病杂志, 2025, 25(7): 661-666.
[13]	张嘉豪, 耿磊, 肖志涛, 陈行, 曹向宇. 脑静脉窦血流动力学研究方法进展[J]. 中国现代神经疾病杂志, 2025, 25(6): 464-469.
[14]	阮玉爽, 董子康, 方芝, 夏远鹏. 脑静脉系统疾病相关炎症机制与干预靶点[J]. 中国现代神经疾病杂志, 2025, 25(6): 470-476.
[15]	郎野, 钟孟飞, 高宗恩. 脑静脉血栓形成抗凝与机械取栓治疗研究进展[J]. 中国现代神经疾病杂志, 2025, 25(6): 477-482.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 PET显像在自身免疫性脑炎诊断与预后预测中的应用

Application of PET imaging in the diagnosis and prognosis prediction of autoimmune encephalitis

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价